Table 1.
Main characteristics of CRC patients with type 2 diabetes mellitus compared by metformin status. Significant values are in bold.
| Variables | All patients (n = 290) | Metformin non-users (n = 146) | Metformin users (n = 144) | p-value |
|---|---|---|---|---|
| Age, years | 73.71 ± 8.70 | 75.05 ± 8.72 | 72.35 ± 8.53 | 0.008 |
| Male sex, n (%) | 201 (69.3) | 95 (65.1) | 106 (73.6) | 0.12 |
| BMI*, kg/m2 | 27.2 [25.0–31.9] | 26.8 [24.0–30.9] | 27.7 [25.6–32.7] | 0.02 |
| Charlson comorbidity index* | 1.0 [0.0–2.0] | 1.0 [0.0–3.0] | 1.0 [0.0–2.0] | 0.10 |
| Complications of diabetes, n (%) | 37 (12.8) | 25 (17.1) | 12 (8.3) | 0.03 |
| Glycemic control, n (%) | 0.23 | |||
| Yes (HbA1c ≤ 7%) | 136 (46.9) | 66 (56.9) | 70 (64.8) | |
| Missing | 66 (22.8) | |||
| Number of drugs/day* | 7.0 [5.0–9.0] | 7.0 [5.0–9.3] | 7.0 [5.0–9.0] | 0.82 |
| Number of antidiabetics/day* | 1.0 [1.0–2.0] | 1.0 [0.0–1.0] | 2.0 [1.0–2.0] | < 0.001 |
| Metformin use, n (%) | 144 (49.7) | |||
| Medications, n (%) | ||||
| Insulin use | 78 (26.9) | 50 (34.2) | 28 (19.4) | 0.004 |
| Sulfonylureas use | 87 (30.0) | 43 (29.5) | 44 (30.6) | 0.84 |
| GLP-1 analogues use | 7 (2.4) | 2 (1.4) | 5 (3.5) | 0.28 |
| AGIs inhibitors use | 16 (5.5) | 5 (3.4) | 11 (7.6) | 0.12 |
| DDP-4 inhibitors use | 44 (15.2) | 14 (9.6) | 30 (20.8) | 0.008 |
| Other glucose-lowering drugs use | 18 (6.2) | 11 (7.5) | 7 (4.9) | 0.35 |
| Diet-alone | 43 (14.8) | |||
| Antihypertensive drugs | 234 (80.7) | 117 (80.1) | 117 (81.3) | 0.81 |
| Hypolipidemic drugs | 147 (50.7) | 65 (44.5) | 82 (56.9) | 0.03 |
| Chemotherapy | 103 (35.5) | 48 (32.9) | 55 (38.2) | 0.34 |
| Neoadjuvant treatment | 37 (12.8) | 16 (11.0) | 21 (14.6) | 0.36 |
*Indicates variables that are not normally distributed.
Quantitative variables are reported as mean ± SD or median [IQR].